Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Catheter EquipmentMedical ImagingCT MRI XrayMolecular Imaging

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 2055534

Cover Image

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 2055534

Angiography Devices

PUBLISHED:
PAGES: 384 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Angiography Devices Market to Reach US$13.2 Billion by 2032

The global market for Angiography Devices estimated at US$9.5 Billion in the year 2025, is expected to reach US$13.2 Billion by 2032, growing at a CAGR of 4.8% over the analysis period 2025-2032. Angiography Systems Type, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in the Catheters Type segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.9 Billion While China is Forecast to Grow at 9.0% CAGR

The Angiography Devices market in the U.S. is estimated at US$2.9 Billion in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$3.3 Billion by the year 2032 trailing a CAGR of 9.0% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Angiography Devices Market - Key Trends & Drivers Summarized

Why Is the Demand for Angiography Devices Surging in Cardiovascular Healthcare?

Angiography devices are experiencing a surge in demand, driven primarily by the increasing prevalence of cardiovascular diseases (CVD) globally. As heart disease remains a leading cause of mortality worldwide, diagnostic procedures like angiography, which provide detailed images of blood vessels, are critical for early detection and treatment. The aging global population, along with unhealthy lifestyle habits such as poor diet and lack of exercise, has led to a rise in conditions like atherosclerosis, stroke, and coronary artery disease. Consequently, the need for reliable diagnostic tools, including angiography systems, is becoming more pronounced in both developed and developing regions. This growth is further supported by healthcare systems emphasizing preventive care and early diagnosis to mitigate the rising costs of treating advanced CVD.

How Is Technology Revolutionizing the Angiography Devices Market?

Technological advancements are playing a pivotal role in enhancing the capabilities of angiography devices, making them more efficient and safer for patients. One major development is the integration of digital imaging technology, which allows for higher-resolution images and real-time monitoring during procedures. The use of 3D and 4D imaging systems is transforming the way cardiologists assess blood vessels and coronary blockages, enabling more precise interventions. Another innovation is the development of minimally invasive catheter-based angiography systems, which reduce patient recovery times and minimize risks associated with traditional invasive angiography. These technological improvements are not only enhancing diagnostic accuracy but also expanding the scope of angiography into peripheral vascular conditions and neurology, thereby broadening the market's reach.

What Role Do Regulations Play in the Adoption of Angiography Devices?

Stringent regulatory requirements are critical to the angiography devices market, as patient safety is paramount in cardiovascular interventions. Regulatory bodies like the FDA and European CE mark demand rigorous testing and validation of these devices to ensure they meet safety and performance standards. These regulations are particularly important given the risks associated with angiographic procedures, such as radiation exposure and contrast-induced nephropathy. Manufacturers are under pressure to develop devices that minimize these risks while complying with strict guidelines. Furthermore, advancements in imaging technologies and the development of contrast-free angiography techniques are being driven by regulatory encouragement, further shaping the future of the market. Compliance with these standards ensures widespread adoption of new, safer angiography systems across global healthcare settings.

What Factors Are Propelling the Growth of the Angiography Devices Market?

The growth in the angiography devices market is driven by several factors, including the rising incidence of cardiovascular diseases, increasing awareness of early diagnostic tools, and advancements in imaging technology. The growing elderly population, who are more prone to heart-related ailments, has significantly boosted demand for angiography procedures. In addition, technological advancements, such as the introduction of hybrid operating rooms that combine surgical and diagnostic functions, are enhancing the efficiency and accuracy of cardiovascular interventions, thereby increasing the demand for state-of-the-art angiography systems. Expanding healthcare infrastructure in emerging markets, coupled with increased government investment in healthcare technologies, is also driving growth. Finally, the growing preference for minimally invasive procedures has accelerated the adoption of newer, safer angiography devices across a range of medical specialties.

SCOPE OF STUDY:

The report analyzes the Angiography Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

End-Use (Hospitals & Clinics, Diagnostic & Imaging Centers, Research Institutes); Procedure (Coronary Angiography, Endovascular Angiography, Neuroangiography, Onco-Angiography, Other Angiography Procedures); Product (Angiography Systems, Angiography Contrast Media, Vascular Closure Devices, Angiography Balloons, Angiography Catheters, Angiography Guidewires, Angiography Accessories); Technology (X-Ray Angiography, CT Angiography, MR Angiography, Other Angiography Technologies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • Abbott Laboratories, Inc.
  • AngioDynamics, Inc.
  • Boston Scientific Corporation
  • Canon Medical Systems Corporation
  • Cordis Corporation
  • GE Healthcare
  • Koninklijke Philips NV
  • Medtronic PLC
  • Shimadzu Corporation
  • Siemens Healthineers

WHAT SETS THIS REPORT APART FROM OTHERS?

Validated Sources - Human-curated validation and ranking of original source content, not AI LLM-generated synthetic content which dominates the internet today and has become a quick fix for most published research reports these days. Unlike most other published sources, our customers have access to full-stack source content. Our report draws from "real intelligence" balancing the power of AI against the risks of synthetically generated content and resulting biases. Customers have access to the source feeds.

Domain Expert Insights - Domain expert insights curated from enterprise, industry, academia, and government, consolidated from multilingual multimedia formats of text, voice, and images comprise a significant resource. Customers can request access to the pool of domain experts we track for this research project. We track 9,699 domain experts and their insights as part of this research project. Our customers may access our online tracker.

Annual subscription - Recommended for maximum value for your research dollar. Provides one additional full update during the 12 months and access to our research portal and interactive 10-user peer-to-peer collaboration drawing from our entire stack of validated project data which is updated on a weekly basis. Platform also enables adding enterprise data or third-party licensed content to build bespoke versions. Includes competitor tracking of up to 50 companies featured in the report.

Show more
Product Code: MCP16146

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Antithrombin - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Thrombosis and Cardiovascular Disorders
    • Growing Demand for Antithrombin in Blood Clot Prevention Therapies
    • Expanding Applications in Genetic and Rare Disorders
    • Increasing Use in Cardiac Surgery and Organ Transplantation
    • Technological Advancements in Recombinant Antithrombin Production
    • Surge in Research for Novel Anticoagulant Drugs
    • Rising Awareness and Adoption in Emerging Economies
    • Increasing Use in Treatment of Heparin-Induced Thrombocytopenia
    • Development of Next-Generation Antithrombin Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Other Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 2: World Historic Review for Other Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 3: World 13-Year Perspective for Other Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
    • TABLE 4: World Antithrombin Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for Antithrombin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for Antithrombin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for Antithrombin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Anticoagulant Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Anticoagulant Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Anticoagulant Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Antiplatelet Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Antiplatelet Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Antiplatelet Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Thrombolytic Drugs Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for Thrombolytic Drugs Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for Thrombolytic Drugs Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Human Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Human Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Human Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Recombinant Goat Milk Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Recombinant Goat Milk Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Recombinant Goat Milk Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Therapeutics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Therapeutics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Therapeutics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Diagnostics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 33: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 34: World 13-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Antithrombin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 36: USA Historic Review for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 37: USA 13-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application, Research Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 38: USA Recent Past, Current & Future Analysis for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 39: USA Historic Review for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 40: USA 13-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human Source, Recombinant Goat Milk Source and Other Sources for the Years 2020, 2026 & 2032
    • TABLE 41: USA Recent Past, Current & Future Analysis for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 42: USA Historic Review for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 43: USA 13-Year Perspective for Antithrombin by Type - Percentage Breakdown of Value Sales for Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 45: Canada Historic Review for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 46: Canada 13-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application, Research Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 48: Canada Historic Review for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 49: Canada 13-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human Source, Recombinant Goat Milk Source and Other Sources for the Years 2020, 2026 & 2032
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 51: Canada Historic Review for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 52: Canada 13-Year Perspective for Antithrombin by Type - Percentage Breakdown of Value Sales for Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type for the Years 2020, 2026 & 2032
  • JAPAN
    • Antithrombin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 54: Japan Historic Review for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 55: Japan 13-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application, Research Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 57: Japan Historic Review for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 58: Japan 13-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human Source, Recombinant Goat Milk Source and Other Sources for the Years 2020, 2026 & 2032
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 60: Japan Historic Review for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 61: Japan 13-Year Perspective for Antithrombin by Type - Percentage Breakdown of Value Sales for Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type for the Years 2020, 2026 & 2032
  • CHINA
    • Antithrombin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 63: China Historic Review for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 64: China 13-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application, Research Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 65: China Recent Past, Current & Future Analysis for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 66: China Historic Review for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 67: China 13-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human Source, Recombinant Goat Milk Source and Other Sources for the Years 2020, 2026 & 2032
    • TABLE 68: China Recent Past, Current & Future Analysis for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 69: China Historic Review for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 70: China 13-Year Perspective for Antithrombin by Type - Percentage Breakdown of Value Sales for Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type for the Years 2020, 2026 & 2032
  • EUROPE
    • Antithrombin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 72: Europe Historic Review for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 73: Europe 13-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application, Research Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 75: Europe Historic Review for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 76: Europe 13-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human Source, Recombinant Goat Milk Source and Other Sources for the Years 2020, 2026 & 2032
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Antithrombin by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 78: Europe Historic Review for Antithrombin by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 79: Europe 13-Year Perspective for Antithrombin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 81: Europe Historic Review for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 82: Europe 13-Year Perspective for Antithrombin by Type - Percentage Breakdown of Value Sales for Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type for the Years 2020, 2026 & 2032
  • FRANCE
    • Antithrombin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 84: France Historic Review for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 85: France 13-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application, Research Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 86: France Recent Past, Current & Future Analysis for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 87: France Historic Review for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 88: France 13-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human Source, Recombinant Goat Milk Source and Other Sources for the Years 2020, 2026 & 2032
    • TABLE 89: France Recent Past, Current & Future Analysis for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 90: France Historic Review for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 91: France 13-Year Perspective for Antithrombin by Type - Percentage Breakdown of Value Sales for Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type for the Years 2020, 2026 & 2032
  • GERMANY
    • Antithrombin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 93: Germany Historic Review for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 94: Germany 13-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application, Research Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 96: Germany Historic Review for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 97: Germany 13-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human Source, Recombinant Goat Milk Source and Other Sources for the Years 2020, 2026 & 2032
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Germany Historic Review for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 100: Germany 13-Year Perspective for Antithrombin by Type - Percentage Breakdown of Value Sales for Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Italy Historic Review for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 103: Italy 13-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application, Research Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 105: Italy Historic Review for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 106: Italy 13-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human Source, Recombinant Goat Milk Source and Other Sources for the Years 2020, 2026 & 2032
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 108: Italy Historic Review for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 109: Italy 13-Year Perspective for Antithrombin by Type - Percentage Breakdown of Value Sales for Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Antithrombin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 111: UK Historic Review for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 112: UK 13-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application, Research Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 113: UK Recent Past, Current & Future Analysis for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 114: UK Historic Review for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 115: UK 13-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human Source, Recombinant Goat Milk Source and Other Sources for the Years 2020, 2026 & 2032
    • TABLE 116: UK Recent Past, Current & Future Analysis for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 117: UK Historic Review for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 118: UK 13-Year Perspective for Antithrombin by Type - Percentage Breakdown of Value Sales for Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 121: Rest of Europe 13-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application, Research Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 124: Rest of Europe 13-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human Source, Recombinant Goat Milk Source and Other Sources for the Years 2020, 2026 & 2032
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 127: Rest of Europe 13-Year Perspective for Antithrombin by Type - Percentage Breakdown of Value Sales for Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Antithrombin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 130: Asia-Pacific 13-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application, Research Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 133: Asia-Pacific 13-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human Source, Recombinant Goat Milk Source and Other Sources for the Years 2020, 2026 & 2032
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 136: Asia-Pacific 13-Year Perspective for Antithrombin by Type - Percentage Breakdown of Value Sales for Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type for the Years 2020, 2026 & 2032
  • REST OF WORLD
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Rest of World Historic Review for Antithrombin by Application - Therapeutics Application, Diagnostics Application, Research Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 139: Rest of World 13-Year Perspective for Antithrombin by Application - Percentage Breakdown of Value Sales for Therapeutics Application, Diagnostics Application, Research Application and Other Applications for the Years 2020, 2026 & 2032
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Rest of World Historic Review for Antithrombin by Source - Human Source, Recombinant Goat Milk Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 142: Rest of World 13-Year Perspective for Antithrombin by Source - Percentage Breakdown of Value Sales for Human Source, Recombinant Goat Milk Source and Other Sources for the Years 2020, 2026 & 2032
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 144: Rest of World Historic Review for Antithrombin by Type - Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 145: Rest of World 13-Year Perspective for Antithrombin by Type - Percentage Breakdown of Value Sales for Anticoagulant Type, Antiplatelet Type and Thrombolytic Drugs Type for the Years 2020, 2026 & 2032

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!